Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: An Eastern Cooperative Oncology Group randomized study (E1588)

Lung Cancer

Volumn 37, Issue 3, 2002, Pages 311-318

  Ettinger, David S ^a   Finkelstein, Dianne M ^b   Ritch, Paul S ^c   Lincoln, Sarah T ^d   Blum, Ronald H ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e Beth Israel Medical Centre   (United States)

Author keywords

Combination chemotherapy; Extensive disease; Ifosfamide; Small cell lung cancer; Teniposide

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; TENIPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER TOXICITY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SIDE EFFECT; SKIN DISEASE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SALVAGE THERAPY; SURVIVAL; TENIPOSIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036753660     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00074-0     Document Type: Article

References (21)

1. Ettinger D.S., Finkelstein D.M., Abeloff M.D., et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J. Natl. Cancer Inst. 84:1992;1077-1084.
2. Ettinger D.S., Finkelstein D., Ritch P., et al. Randomized trial of single agents vs. combination chemotherapy in extensive stage small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 11:1992;295.
3. Woods R.L., Fox R.M., Tattersall M.H.N. Treatment of small cell bronchogenic carcinoma with VM-26. Cancer Treat. Rep. 63:1979;2011-2013.
4. Bork E., Hansen M., Dombernowsky P., et al. Teniposide (VM-26), an overlooked highly active agent in small cell lung cancer. Results of a phase II trial in untreated patients. J. Clin. Oncol. 4:1986;524-527.
5. Drings P. Ifosfamide in the treatment of bronchial carcinoma. Contrib. Oncol. 26:1987;294-318.
6. Loehrer P.J., Birch R., Kramer B.S., et al. Ifosfamide plus N-acetylcysteine in the treatment of small cell and non small cell carcinoma of the lung: a Southeastern Cancer Study Group trial. Cancer Treat. Rep. 70:1986;919-920.
7. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
8. Issell B.F., Einhorn L.H., Comis R.L., et al. Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treat. Rep. 69:1985;127-128.
9. Johnson D.H., Hainsworth J.D., Hande K.R., et al. Current status of etopside in the management of small cell lung cancer. Cancer (Suppl.). 67:1991;231-244.
10. Clark P., Talbot D., Price C., et al. Single agent etoposide in untreated extensive small cell lung cancer. Lung Cancer. 4:1988;A108.
11. Creech R.H., Tritchler D., Ettinger D.S., et al. Phase II study of PALA, amsacrine, teniposide and zinostatin in small cell lung carcinoma (EST 2579). Cancer Treat. Rep. 68:1984;1183-1184.
12. Pedersen A.G., Bork E., Osterlind K., et al. Phase II study of teniposide in small cell carcinoma of the lung. Cancer Treat. Rep. 68:1984;1289-1291.
13. Ettinger D.S., Finkelstein D.M., Sarma R.P., et al. Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 13:1995;1430-1435.
14. Jett J.R., Kirschling R.J., Jung S.H., et al. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer. A study of the North Central Cancer Treatment Group. Semin. Oncol. 22:(Suppl 6):1995;75-77.
15. Hesketh P.J., Growley J.J., Burris H.A., et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group Phase II Trial. Cancer J. Sci. Am. 5:1999;237-241.
16. Schiller J.H., Kim K., Hutson P., et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 14:1996;2345-2352.
17. Masuda N., Fukuoka M., Kusunoki Y., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. 10:1992;1225-1229.
18. Negoro S., Fukuoka M., Niitani H., et al. A phase II study of CPT-11, a campothecin derivative in patients with primary lung cancer. Jpn. J. Cancer Chem. 18:1991;1013-1019.
19. Depierre A., LeChevalier T., Quoix E., et al. Phase II study of Navelbine (NVB) in small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 14:1995;348a. (Abstr. 1050).
20. Cormier Y., Eisenhauer E., Muldal A., et al. Gemcitabine is an active new agent in previously untreated small cell lung cancer (SCLC). Ann. Oncol. 5:1994;283-285.
21. Negoro T., Takada Y., Yokota S., et al. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline in previously untreated patients with extensive stage small cell lung cancer (ES-SCLC): a West Japan Lung Cancer Group Trial. Proc. Am. Soc. Clin. Oncol. 17:1998;450a. (Abstr. 1734).